Get a full analysis report for any ticker →

SECTOR COVERAGE

Biotech Stock News

50 STORIES · UPDATED 4D AGO

In biotech the whole thesis often hinges on one FDA decision or trial read-out. We track the catalysts and the cash runway behind them, because a promising pipeline means little if the balance sheet runs dry before approval.

By Basis Report Editorial DeskReviewed by Basis Report Methodology TeamMethodology
Top StoryIBRX

ImmunityBio Surges 11% as ANKTIVA Sales Drive 94% Revenue Growth

ImmunityBio's Q4 showed 94% YoY revenue growth driven by ANKTIVA commercial sales, lifting the stock 11%, but the company burns more cash than it earns and a 31% short float amplified the move.

IONSAnalysis

Ionis CSO Sells $1.7M as Stock Falls to $44 vs $84 Target

Three Ionis executives, including the Chief Scientific Officer, sold $2.6 million in shares at $83-$85 in July. The stock has since fallen 46% to $44.…

SMMTBrief

AstraZeneca Backs Summit Therapeutics With $2 Billion Investment

AstraZeneca invested $2 billion in Summit Therapeutics while strong ivonescimab lung cancer survival data hit simultaneously, removing the capital-fai…

TWSTAnalysis

Twist CEO Sells $56M at Rally Peak, Stock Tops Targets

Twist Bioscience CEO Emily Leproust sold $56.33M on September 17 at the peak of a 33% rally tied to the Lilly TuneLab partnership, cashing out deeply …

SMMTAnalysis

Summit Therapeutics Phase III Beats Keytruda, Burns $458M

Summit Therapeutics' ivonescimab achieved Phase III superiority over pembrolizumab in non-small cell lung cancer, posting 30.8 months median overall s…

SMMTAnalysis

Summit's NSCLC Data Tops Keytruda, Cash Runway Tightens

Summit Therapeutics' ivonescimab outperformed Keytruda in a China lung cancer trial, a major clinical win. Yet the company raised equity twice in six …

PRAXAnalysis-12%

PRAX Falls 12% After Trial Setback Following Analyst Boost

Praxis Precision Medicines dropped 12% after-hours following a trial setback, just three days after analysts issued upgrades projecting 91% upside. Wi…

NAMSAnalysis

NAMS CSO Sold $3.4M Before Phase 3 Data Readout

NewAmsterdam Pharma's Chief Scientific Officer sold $3.4M worth of shares on August 24, immediately before the company's Phase 3 Obicetrapib data read…

PLSEAnalysis

Pulse Bio COO Buys Above Analyst Target at All-Time High

Pulse Biosciences COO bought nearly $200K of stock above analyst targets as shares hit all-time highs, signaling conviction in the company's cardiac c…

PBLSAnalysis

Parabilis Medicines: Why Ra Capital Keeps Buying $5B Bet

Parabilis Medicines, valued at $5 billion with zero revenue, posted a -772.6% EPS miss in its first public quarter. Yet Ra Capital, which anchored the…

PBLSAnalysis

Parabilis Q2 EPS Miss Doesn't Deter Ra Capital Buying

Parabilis Medicines reported a Q2 EPS of -$2.12, missing consensus by 772.6% on zero trailing revenue. Despite this, Ra Capital—which invested $394 mi…

MBXAnalysis-7.5%

MBX Biosciences Stock Falls 7.5% on Phase 3 Trial Launch

MBX stock fell 7.5% on the Phase 3 trial launch announcement, but the market was actually reacting to the Q2 earnings miss that signaled potential los…

MANEAnalysis

Veradermics Insiders Sold $103M as Stock Peaked

Veradermics insiders including the CEO, CTO, and a board director collectively sold $103.12 million in stock at $106 to $111 per share in the two week…

ARWRAnalysis

Arrowhead's 750-Patient Heart Data: A $12B Test

Arrowhead Pharmaceuticals carries a $12 billion market cap sustained entirely by episodic milestone payments from GSK, Takeda, Amgen, and Sarepta, wit…

ARWRAnalysis

Arrowhead Directors Sell $1.19M Ahead of Key Heart Data

Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18, days before a 750-patient cardiovascular dataset is due …

ALMSAnalysis

Alumis: Six Officers Sold at $26.37 on a 10% Down Day

Six Alumis executives sold 14,953 shares at $26.37 on August 3, a session where the stock fell 10%, generating roughly $394,000 in combined proceeds p…

ARWRAnalysis

Arrowhead Directors Sell $1.2M as REDEMPLO Nears EU Vote

Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in stock on August 18 while shares were gaining 7% on European REDEMPLO regulato…

NAMSAnalysis

NewAmsterdam Pharma: CAO Sold $6.7M, Stock Below Floor.

NewAmsterdam Pharma's CAO sold $6.71 million in shares across three months at prices between $29.96 and $35.69, and the stock now trades at $27.79, be…

TRVIAnalysis

Trevi Therapeutics: Fidelity Buys 8.8% After Q2 Miss

Trevi Therapeutics posted a second consecutive EPS miss in Q2 2026 while FMR LLC disclosed an 8.8% ownership stake, with institutional investors colle…

TWSTAnalysis

Twist Bioscience Insiders Sell $25M Into AI-Driven Rally

Twist Bioscience shares trade roughly 29% above analyst consensus on a reported guidance hike and Anthropic-linked AI announcement, yet insiders net-s…

IONSAnalysis

Ionis Insiders Sold at $85, Then Bought at $52

Goldman Sachs raised its Ionis Pharmaceuticals price target today, lifting shares 4% in after-hours trading, yet the stock sits roughly 28% below the …

AMLXAnalysis

Amylyx Files Offering Same Day as Phase 3 Win

Amylyx Pharmaceuticals surged 45% after Avexitide posted positive Phase 3 results for post-bariatric hypoglycemia and congenital hyperinsulinism, cond…

AMLXBrief+45%

Amylyx Pharmaceuticals Jumps 45% as Trial Cuts Hypoglycemia by 55%

Amylyx Pharmaceuticals surged 45% in a single trading session after its experimental drug showed a 55% reduction in dangerous hypoglycemia events, a c…

IBRXAnalysis

ImmunityBio Directors Sold $3.9M Before Earnings Miss

Three ImmunityBio directors completed $3.92 million in open-market share sales between June 4 and July 2, before an August 4 earnings report that disc…

IBRXAnalysis

ImmunityBio Insiders Banked $3.92M Above Current Price

Three ImmunityBio directors sold $3.92M in shares at $7.18-$9.50 weeks before the company reported its worst EPS miss in four quarters, a -175% shortf…

IBRXAnalysis

ImmunityBio Directors Sold $3.92M Before Earnings Miss

Three ImmunityBio board members sold $3.92 million in shares at prices between $7.18 and $9.50 between June 4 and July 2, 2026, weeks before the compa…

ATAIAnalysis

AtaiBeckley Beats: Lilly Takes the Upside

AtaiBeckley delivered a 17.9% EPS beat, its first in at least four quarters, at the same moment Eli Lilly's $6.75 acquisition locked the ceiling on sh…

SMMTAnalysis

Summit Therapeutics CEOs Spend $100M Buying Own Stock

Summit Therapeutics co-CEOs Robert Duggan and Mahkam Zanganeh each bought 3,810,000 shares at $13.12 on June 12, committing a combined $100 million of…

ATAIAnalysis

ATAI: Insiders Sold at $5, Lilly Bid $6.75

AtaiBeckley has agreed to a $6.75-per-share cash acquisition by Eli Lilly, with Reuters pegging total value at up to $3.8 billion, as shares trade at …

PRAXAnalysis

Praxis Jumps on FDA Checks, Vormatrigine Misses Phase 3

Praxis Precision Medicines jumped 15.95% on August 6 after FDA mid-cycle reviews flagged no significant efficacy issues and clinical site inspections …

ARWRAnalysis

ARWR Jumps on Phase 3 Trial Win, Analysts Raise Targets

Arrowhead Pharmaceuticals surged after positive Phase 3 results that analysts called a "best-case scenario," with Piper Sandler and Chardan raising ta…

PVLAAnalysis

Palvella COO Logs Third Month of Open-Market Sales

Palvella Therapeutics COO Kathleen Goin sold approximately $642,000 in company shares on July 15, completing a third consecutive month of identical 4,…

RGCAnalysis+12%

Regencell Stock Surges 12% With Class Actions Pending

Regencell Bioscience Holdings climbed 12% on July 22 with no identifiable catalyst in public filings, even as securities class actions from two law fi…

ORKABrief

Oruka Therapeutics Expands IL-23 Drug Rights But Delays Key IBD Trial

Oruka Therapeutics widened its IL-23 indication rights but delayed IBD dosing timelines, removing a near-term catalyst while Piper Sandler held its Ov…

MANEBrief

Veradermics Hair-Loss Pill Posts Positive Results in 500-Man Trial

Veradermics' experimental oral hair-loss pill returned positive results in a 500-man trial, marking a key clinical milestone that could accelerate the…

APLSAnalysis

Biogen Closes $5.6B Apellis Acquisition, APLS Delisted

Biogen completed its $5.6 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, paying $41.00 per share in cash plus a contingent value righ…

IBRXAnalysis

ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its A…

IBRXBrief

ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk …

OGNBrief

Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price

Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.

UECBrief

Uranium Energy Corp Pops 9.7% on Burke Hollow Approval, First New U.S. ISR Project in Years

Uranium Energy Corp shares rose 9.7% after Burke Hollow became the first new U.S. ISR uranium project to launch in years, with Vanguard disclosing a 5…

ERASAnalysis-40%

Erasca Plunges 40% on Trial Death, Patent Threat

Erasca shares collapsed roughly 40% in after-hours trading after Phase 1 data for ERAS-0015 revealed a treatment-related patient death alongside other…

ORKABrief

Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering

Oruka Therapeutics surged to a record high after Phase IIa data showed 64% skin clearance for its once-yearly psoriasis drug, then launched a $500M pu…

RCUSBrief

Arcus Biosciences Stock Rebounds 7.8% After Lung Cancer Trial Fails — Here's the Twist

Arcus Biosciences discontinued its Phase 3 lung cancer trial for futility, but the stock rebounded 7.8% as analysts flagged Merck's belzutifan failure…

NKTRBrief

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move…

LEGNBrief+18%

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best sessi…

KLRABrief

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense…

TNGXBrief

Tango Therapeutics Overhauls C-Suite With Three Senior Hires to Push Pancreatic Cancer Drug Toward Approval

Tango Therapeutics appointed Matthew Gall as CFO and hired two additional senior executives to accelerate late-stage development of pancreatic cancer …

TVTXBrief+33%

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidne…

SYREBrief

Spyre Therapeutics Hits 4-Year High on Trial Win, Then Sells $300 Million in Stock

Spyre Therapeutics' SPY001 met all Phase 2 endpoints for ulcerative colitis, prompting analyst upgrades and a 4-year share price high, but the company…

TLXBrief

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-reven…

Keep going

Sample Reports
See a full teardown end to end — DCF, earnings-quality score, and red flags on AAPL, NVDA, MSFT and more.
Browse the reports →
Free Tools
148 calculators — DCF, earnings-quality scorer, capital-allocation grader. No signup, no card.
Open the tools →
The Field Guide
50 plain-English chapters on valuation and earnings quality — how to read a filing the way we do.
Start reading →

Your move

Run this same teardown on a stock you actually own.

Drop in any ticker and get an institutional-grade report in about 60 seconds — the full DCF, an earnings-quality score, and the red flags buried deep in the filing. No signup, no card.

Run a free report →
  • DCF valuation with bull & bear cases
  • Earnings-quality score from 0–100
  • Red-flag scan across the 10-K
  • Peer multiples & a fair-value range